For instance, polyinosinic/polycytidylic acid (PolyIC), a well-known dsRNA analog, have shown efficacy in cancer immunotherapy through Toll-like receptors 3 (TLR3) triggered innate immune and entered clinical trials [307]. The gene discussed is TLR3; the disease is cancer.